Are Teva Pharmaceutical (NYSE:TEVA) Shares Headed North? BTIG Research Issues Upgrade

Posted September 13, 2017

Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a buy rating to a strong-buy rating and set a $34.25 target price on the stock in a research report on Wednesday, May 17th. Credit Suisse Group cut shares of Teva Pharmaceutical Industries Limited from a neutral rating to an underperform rating and cut their price objective for the stock from $25.00 to $13.00 in a research report on Wednesday, August 23rd. Stifel Nicolaus maintained the shares of LSTR in report on Thursday, October 20 with "Hold" rating. While the stock price moved along with the volume change, shares are touching $19.29.

Cantor Fitzgerald set a $17.00 target price on Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research note published on Monday. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $52.66. In addition to its complexity and widely diversified business, Teva faces many challenges in its business environment and a great deal of leverage, "Leader Capital Markets Ltd".

It is trading at $18.50 which is quite a bit lower than the 50 day moving average which is $20.66 and quite a bit lower than the 200 day moving average of $29.02. (NASDAQ:ULBI). Morgan Stanley stated it has 1,243 shares or 0% of all its holdings. Therefore 25% are positive. The firm's revenue for the quarter was up 12.9% compared to the same quarter past year.

However, the analyst further underlines the pressure that Schulz will face from generics and debt, noting: "Shultz will be entering the company at a turbulent time, given: (1) continued pricing pressure in United States generics; (2) TEVA's meaningful debt and inability to de-lever in a timely manner; and (3) high likelihood of Copaxone 40mg generics in 2018". The company reported $0.99 earnings per share for the quarter, missing analysts' consensus estimates of $1.06 by $0.07. Also, the current price highlights a discount of 82.08% to analysts' high consensus price target. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and worldwide trademark and copyright law. The company recently declared a dividend for shareholders to be paid on Thursday the 14th of September 2017. Barclays Capital maintained it with "Equal Weight" rating and $38 target in Tuesday, January 31 report. The dividend yield will be $7.14. Teva Pharmaceutical Industries Limited's dividend payout ratio (DPR) is now 67.44%. From the opening price, the stock has seen a change of -3.75% recently clocking in with a price of $19.24. Bronfman E.L. Rothschild L.P. grew its holdings in Teva Pharmaceutical Industries Limited by 7.8% during the first quarter. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Buy" rating given on Thursday, July 14 by Jefferies.

Sphera Funds Management Ltd increased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 29.85% based on its latest 2016Q4 regulatory filing with the SEC.

The Coca-Cola Company (NYSE:KO)'s stock on Monday traded at beginning with a price of $46.35 and when day-trade ended the stock finally surged 0.48% to reach at $46.52. Washington Trust Bank boosted its position in Teva Pharmaceutical Industries Limited by 2.7% in the third quarter. WFG Advisors LP increased its position in Teva Pharmaceutical Industries Limited by 2,650.1% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company's stock worth $125,000 after buying an additional 100 shares during the last quarter.

The new chief, only the second non-Israeli to lead the company, also understands the "cultural framework" of working for a pharmaceutical companies firm that like Novo Nordisk is also considered a national champion, Mr. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Firm operates through two divisions: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.